Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. - Wikidata - wikimedia - TriplyDB

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.

http://www.wikidata.org/entity/Q35006904

about

HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.Tumour heterogeneity in the clinic.The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer.Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis Current status of novel agents in advanced gastroesophageal adenocarcinoma.Recent advances in the HER2 targeted therapy of gastric cancer Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis.Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).Targeted therapy for esophagogastric cancers: a review Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis.Gastric cancer and trastuzumab: first biologic therapy in gastric cancer.Her2/neu testing in gastric cancer: evaluating the risk of sampling errors HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series.Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma.HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases.Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes.Change of HER2 status in metastatic esophageal adenocarcinoma: heterogeneity of the disease? Case report and review of literature.Targeting the human epidermal growth factor receptor 2 in esophageal cancer.The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.HER2 assessment by silver in situ hybridization: where are we now?Evolution and emerging future of cytoreducxtive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: From treating the incurable to preventing recurrence.HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis.Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer.Are biopsy specimens predictive of HER2 status in gastric cancer patients?Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer.

P2860

Q26741253-763321CD-4B8E-467E-9BAB-36CEB3FA1DB3 Q26780318-1B77140E-AEB3-4B0C-9246-0767B1AFEC36 Q26822730-03A88EC7-5A34-4819-A0C8-4A26B866680F Q28077666-C91D9CA5-0059-4E1B-87E8-0D451CBAF976 Q28078788-8FDBB774-64BF-4836-8BD2-0C9EF0163742 Q33761681-2041E126-20B1-405B-B354-CDE6D8CC4AFB Q34033475-98D722B3-D8F9-4CB0-801D-837FFD347F69 Q34324291-16C0929B-7B33-4C1C-99B2-F5B512CF80F5 Q34372080-4F93A7F9-3A90-499C-8248-4EE3EA7E7930 Q34648886-B811EF15-EEB6-4172-A05E-69BCD08A744C Q34834419-9BCE27F4-2A51-4AF2-8FC4-F5422AE8227D Q34962039-E6ADC807-F2A7-4733-8648-72EB8AD60441 Q34967104-D1417F5C-55C1-407E-AB44-2B13E4C58618 Q35525379-1551B001-B3FF-4381-8A1D-3BAC2501AF87 Q35538755-8248A080-1B9B-4E42-A77D-4B93458C0293 Q36027093-0F482F65-4645-4FCF-85B7-C0B5A9DDF11E Q36039645-FB60D92C-A096-477C-8978-42B172A116C2 Q36220464-36FA6707-8942-4A88-B5B5-C7B44A8C4861 Q36477708-42C4BDC6-E1BC-47F0-9396-D6F64BAD9F49 Q36567393-F755F231-EB88-4FD5-9921-695E73742A4D Q36615782-9A5E6243-1F83-4504-B0E2-3B7A64A473BC Q36655951-5B9B1CB2-A87D-448D-8FBF-6FD43DFF7FAC Q36666667-F248BF7F-5CAE-4388-A335-2C6569F75C53 Q36849324-030D3356-601F-46FA-8D99-49AF0825CAE4 Q37241496-A341AE83-0685-4ECA-A5EE-EEDE276EC711 Q37373790-0C9FEE6A-0B5F-4ACE-9D65-32AFFF0DA7CE Q37607824-9C2E2B70-8924-4A97-9688-B02570467BE3 Q38064466-E7147D71-B1DD-431D-9667-3B183E734759 Q38097675-5912B62E-366C-46F1-9A23-96F490AA9C96 Q38210070-BD6CA9A7-170E-46AE-915B-2DF7F5A90F1F Q38314355-F78A2C97-9E67-4A80-A140-AED41C4DEDC5 Q38931710-987EEB38-F540-4C49-A200-CBA709FD562F Q39080349-1F233E9D-59DF-4384-ABA6-2ED3C34FAD5A Q39363485-42F0ECC3-8D78-4B44-8196-61B66D211DEC Q39535768-F47BFC6D-6E7D-4D01-AEA0-9400F784391F Q39706220-D79ADF87-43B3-45B4-8A8F-E62AA578B519 Q41812451-CF8D9B91-6043-46AE-9577-B7C1365B5DEE Q44885327-AA68DC32-CECB-49F5-B742-9F125D05C3C3 Q46129222-68F96CF4-3420-4EAB-9D74-26F3DAE9CEBF Q47096927-7121BB0E-B57B-43EB-A34A-D65C7D8A1EC1

P2860

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.

http://www.wikidata.org/entity/Q35006904

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.

@ast

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.

@en

type

label

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.

@ast

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.

@en

prefLabel

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.

@ast

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.

@en

P1433

Q35006904-0C2C57B1-C55A-4AC6-B249-F7AB0056C65F

P1476

Q35006904-BC0DFF15-3767-4AE3-AB3B-F56847B2E99F

P2093

Q35006904-13856C4C-8E79-4950-8F1A-5369FF534A53

Q35006904-169CB8F6-D70D-47E2-994D-77F7EE27D0A8

Q35006904-18861728-9495-44F5-9F1A-A048768DF1F9

Q35006904-59B833D0-F705-4A2C-9379-85CDB1BCB5B2

Q35006904-662AFAA2-D6E6-406E-9938-141E526EC89B

Q35006904-7349FFCB-D346-489D-93E1-62F0FBEE4D09

Q35006904-96FB8A72-26B5-4F1E-977C-37CD76647893

Q35006904-98A760BF-700D-4765-90DF-373EA5DFA288

Q35006904-9B919E34-33D7-4711-88D1-A271EA73AD4C

Q35006904-A0D839FD-98F6-48DA-A005-189E91A7F5E2

P2860

Q35006904-45A8F935-392E-4008-8D4E-67D334D8FD1D

Q35006904-596A30F6-9A72-44BD-BBDB-93F01DDED05D

Q35006904-6BBE6323-E7BB-43A6-9BC4-CE838C996CD5

Q35006904-6C889F7E-7D1E-4F9E-87A3-C578CEFB4772

Q35006904-84CD3D08-6774-4008-8006-8388928CB670

Q35006904-A2CD0129-89F5-46D1-AA03-14FDBAEB7187

Q35006904-AB9D8F74-B736-4C37-9BE0-E70686A67AD0

Q35006904-B795899D-923B-489A-9DE6-C620917019BF

Q35006904-D3F89DD5-FA7E-416B-9085-BF9A36671625

Q35006904-E5EEA98F-539F-4430-BAAD-2FBC5B3ECC19

P2888

Q35006904-C3E95A4D-17F5-4DB9-8558-2207A7BE7F16

P304

Q35006904-94AADA09-01AE-49B6-A81A-A4CD7C1FD823

P31

Q35006904-99656854-64F9-46E8-A13D-E8ED2B916E18

P356

Q35006904-17770136-834D-4093-B4D8-310839E05FAF

P407

Q35006904-106D255D-6F9C-4000-A042-390757AF9680

P433

Q35006904-E81AAC7C-8957-44F9-9BD2-5CDD9D13A3B0

P478

Q35006904-EF45516F-3EE3-4A3D-AB79-C093B890731B

P577

Q35006904-7BD857ED-EF35-472B-B900-FEE2D3DA6FAD

P5875

Q35006904-EFBC5685-8315-470F-AB53-D040D18E41CD

P698

Q35006904-A77B73EA-AD93-4A71-99EC-03E0A1C0E9BC

P932

Q35006904-374F1ABA-93B6-4A8B-B607-BDEC26A96BD0

P356

P1433

British Journal of Cancer

P1476

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.

@en

P2093

A Ardizzoni

http://www.w3.org/2001/XMLSchema#string

C A Lagrasta

http://www.w3.org/2001/XMLSchema#string

C Bassano

http://www.w3.org/2001/XMLSchema#string

C Bozzetti

http://www.w3.org/2001/XMLSchema#string

D Gasparro

http://www.w3.org/2001/XMLSchema#string

E M Silini

http://www.w3.org/2001/XMLSchema#string

F Leonardi

http://www.w3.org/2001/XMLSchema#string

F V Negri

http://www.w3.org/2001/XMLSchema#string

G Gardini

http://www.w3.org/2001/XMLSchema#string

I Tamagnini

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients

Assessment of a HER2 scoring system for gastric cancer: results from a validation study.

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma.

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

HER-2 amplification is highly homogenous in gastric cancer.

Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.

P2888

P304

1372-1376

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2011.121

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51046049

http://www.w3.org/2001/XMLSchema#string

P698

21487407

http://www.w3.org/2001/XMLSchema#string

P932

3101935

http://www.w3.org/2001/XMLSchema#string